And never invest or trade money you cannot afford to lose. Receive regular, detailed analysis focused on biotech and healthcare stocks. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. $163.64. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. What guidance has AbbVie issued on next quarter's earnings? Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. How often does AbbVie pay dividends? AbbVie income statement forecast (My table and assumptions). That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. Since then, however, the stock price has fallen 18% to its current price of $142.6. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. For the next eight years, the forecast is for Free Cash Flow to grow by . RHHBY vs. ABBV: Which Stock Is the Better Value Option? The company didn't offer a . A Warner Bros. What is the dividend yield for AbbVie? GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. As such, forecasting stock prices is more of an art than a science. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. . Real-time analyst ratings, insider transactions, earnings data, and more. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. The material provided on this website is for information purposes only and should not be understood as an investment advice. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. My No. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. AbbVie Stock Forecast 03-06-2023. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Most stock quote data provided by BATS. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: If you have an ad-blocker enabled you may be blocked from proceeding. The analysts 12-month consensus ABBV stock price target was $159.75. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. I write about Biotech, Pharma and Healthcare stocks and share investment tips. View AbbVie's Short Interest. Please disable your ad-blocker and refresh. Retail sales were up but so was inflation which meant more volatility for stocks. Should I buy or sell AbbVie stock right now? Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Our daily ratings and market update email newsletter. I hope to see you there. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. During the same quarter in the prior year, the firm posted $3.31 EPS. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Past performance is no guarantee of future results. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. I'm on twitter @edmundingham. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. This indicates that the company will be able to sustain or increase its dividend. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Shares are consolidating with a buy. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. This would represent an increase of 1.78%. On average, they expect the company's stock price to reach $161.12 in the next twelve months. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Their ABBV share price forecasts range from $140.00 to $200.00. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. Discovery Company. PEG Ratios above 1 indicate that a company could be overvalued. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. On average, they predict the company's stock price to reach $161.12 in the next year. The company has a robust pipeline of new products that are in some stage of clinical trials. Sign in to your free account to enjoy all that MarketBeat has to offer. Receive ABBV Stock News and Ratings via Email. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Forecast target price for 03-06-2023: $ 152.58. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Is this happening to you frequently? z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. ABBV has several positive factors pushing its price performance. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. I wrote this article myself, and it expresses my own opinions. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . Read the conference call transcript. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. The Abbvie stock forecast for 2025 had the price at $259.018. This suggests a possible upside of 3.2% from the stock's current price. Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. AbbVie's stock was trading at $161.61 on January 1st, 2023. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. All Rights Reserved. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. I have no business relationship with any company whose stock is mentioned in this article. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. What other stocks do shareholders of AbbVie own? (844) 978-6257. The company reported its first revenue for Botox competitor Daxxify. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? The company is focused on research and has a number of collaborations and partnerships to that end. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. Receive regular, detailed analysis focused on biotech and healthcare stocks. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. In February, a Phase 3 induction study saw positive top-line results. What is AbbVie's stock price forecast for 2023? Always conduct your own due diligence before investing. AbbVie discounted cash flow analysis. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. That was below AbbVie stock analysts' view for $14.16. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth.